Roche reports positive lung cancer data for Tecentriq-based treatment regimen

Roche has announced new clinical trial data that demonstrates the benefits of a Tecentriq-based treatment regimen for advanced lung cancer.

Results from the phase III IMpower150 study have shown the progression-free survival benefits offered by a combination of Tecentriq and Avastin plus chemotherapy in the first-line treatment of people with advanced non-squamous non-small cell lung cancer (NSCLC).

The regimen was shown to provide a statistically significant and clinically meaningful reduction in the risk of disease worsening or death compared to Avastin plus chemotherapy alone, while initial observations for overall survival gains are also encouraging.

Data from this study will be submitted to health authorities globally, including the US Food and Drug Administration and the European Medicines Agency, to support future regulatory decisions.

Dr Sandra Horning, Roche's chief medical officer and head of global product development, said: "We are extremely encouraged by these results and will submit this data to health authorities globally with the goal of bringing a potential new standard of care for the initial treatment of lung cancer."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.